Table 1.
Esophagectomy | Ablation | P value | |
---|---|---|---|
N | 79 | 80 | |
Age at treatment | 63.1 ± 10.6 | 69.7 ± 9.4 | <0.0001 |
Male gender | 73 (92%) | 64 (80%) | 0.02 |
Vital status: deceased | 10 (13%) | 8 (10%) | 0.60 |
Length BE (in cm)* | 6.6 ± 3.7 | 5.4 ± 3.7 | 0.03 |
Co-morbid diagnoses | |||
CAD | 19 (24%) | 21 (26%) | 0.75 |
CHF | 6 (8%) | 5 (6%) | 0.74 |
COPD | 5 (6%) | 9 (11%) | 0.27 |
Cancer stage | |||
HGD/IMC | 28 (35%) | 70 (88%) | <0.0001 |
T1sm | 8 (10%) | 6 (8%) | |
T2 or greater | 43 (54%) | 4 (5%) | |
Initial consultant | |||
Gastroenterologist | 32 (41%) | 76 (95%) | <0.0001 |
Surgeon | 42 (53%) | 4 (5%) | |
Oncologist | 5 (6%) | 0 |
Pre-treatment length of Barrett’s esophagus not recorded in 24 patients in esophagectomy group, and 4 patients in ablation group.